Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Exact Sciences (EXAS) Ahead of Earnings?

MADISON, Wis., July 8, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call. Annual Meeting of Stockholders Webcast Details Date: Thursday, July 23, 2020 Time:...

Exact Sciences schedules annual meeting, second quarter 2020 earnings call

CareDx

Cigna

Quest Diagnostics

It is very possible by now that many adults have had a telehealth conference or checkup.

Telehealth Is Here to Stay: 4 Stocks to Buy Now With Huge Potential

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Why Is Exact Sciences (EXAS) Up 2.4% Since Last Earnings Report?

This cancer diagnostic company could make you wealthier, just not seven-figures wealthier.

Could Exact Sciences Be a Millionaire-Maker Stock?

Q1 results were mixed, but the company’s strategy may be key for top-line growth ahead.

Is Exact Sciences Stock a Buy?

Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.

Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands

Exact Sciences Corp (EXAS) CEO Kevin Conroy on Q1 2020 Results - Earnings Call Transcript

Etsy

Franco-Nevada C

Shopify

Scotts Miracle-Gro

Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates tomorrow.

Buy 5 Top Stocks Set to Beat Earnings Estimates Tomorrow

Jazz Pharmaceuticals

These stocks have a track record of revenue growth, and more is to come.

2 Cheap Healthcare Stocks to Buy Now

As of late, it has definitely been a great time to be an investor in Exact Sciences.

Exact Sciences' Shares March Higher, Can It Continue?

Exact Sciences: This Cancer Diagnostics Stock Is Cheap Enough To Buy In 2020

Livongo Health Inc

These two companies have exciting growth opportunities ahead and could make your money work for you.

2 Stocks That Could Double Your $1,200 Stimulus Check

Tandem Diabetes Care

58.com

The coronavirus may have temporarily slowed them down, but some businesses are built better than others to shrug off the COVID-19 contagion.

3 High-Growth  Stocks That Could Soar

Exact Sciences: Well Positioned To Execute In FY20

Exact Sciences (EXAS) closed at $60.89 in the latest trading session, marking a -0.56% move from the prior day.

Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know

Exact Sciences (EXAS) progressing well in terms of the company's three priorities.

Exact Sciences Grows on New Deals, Down on Coronavirus Scare

The growth stock has become a value stock.

Exact Sciences Withdraws Guidance, Shares Still Jump 32%

Myriad Genetics

Invitae

Have these growth stocks bottomed out? That's probably the wrong question to ask.

Genetic Testing Stocks Rise Again as Volatility Continues

Align Technology

Bausch Health Companies Inc

More coronavirus worries. More misery for these healthcare stocks.

Why Align Technology, Bausch Health, and Exact Sciences Stocks Tanked Today

NeoGenomics

Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.

Here's Why Genetic Testing Stocks Are Down Today

Shockwave Medical

Why Exact Sciences, Align Technology, and ShockWave Medical Shares Are Plunging Today

Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?

HealthEquity

Senseonics Holdings

An overall market sell-off stemming from increased coronavirus worries weighed on all three healthcare stocks.

Why Exact Sciences, HealthEquity, and Senseonics Holdings Stocks Tanked Today

This high-growth healthcare stock should be poised for a huge rebound in the not-too-distant future.

News for Exact Sciences Stock (EXAS)